Clinical medicine profile
Mecobalamin/alpha lipoic acid/ folic acid/ selenium dioxide/inositol/and chromium polynicotinate
Vitamin / mineral / nutritional supplement
- Route
- ORAL / IM / IV (selected)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Mecobalamin] Hypervitaminosis risk states (hypercalcaemia for vitamin D/A).
- Iron: avoid in iron overload.
- Potassium: severe hyperkalaemia / untreated Addison's. [alpha lipoic acid] Hypervitaminosis risk states (hypercalcaemia for vitamin D/A).
- Iron: avoid in iron overload.
- Potassium: severe hyperkalaemia / untreated Addison's. [folic acid] CONTRAINDICATIONS: Integra FTM is contraindicated in patients with known hypersensitivity to any of its ingredients
- also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias.
- Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.
Precautions
- [Mecobalamin] Treat confirmed deficiency with monitored repletion.
- Avoid megadoses without indication.
- Iron: keep away from children (overdose lethal). [alpha lipoic acid] WARNINGS Stop use and ask doctor if symptoms persist more than 5 days or worsen.
- If pregnant or breast-feeding ask a health professional before use.
- Keep out of reach of children. [folic acid] WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6.
- Keep this product out of reach of children.
- In case of accidental overdose, call a doctor or poison control center immediately.
- WARNING: Folic acid alone is improper therapy in the treatment for pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient.
- PRECAUTIONS: General: Anemia is a manifestation that requires appropriate investigation to determine its cause or causes.
- No single regimen fits all cases and the status of the patient observed in follow-up is the final criterion for adequacy of therapy.
- Periodic clinical and laboratory studies are considered essential.
- Blood examinations including hemoglobin and hematacrit should be done at the usual intervals to make certain that therapy is adequate.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Fat-soluble vitamins and potassium need care in advanced CKD.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Vitamin A toxicity hepatic; niacin hepatotoxicity at high dose.
Use, effects & interactions
Indications
- Prophylaxis and treatment Vitamin B12 deficiency and other nutrients Clinical selection for Mecobalamin/alpha lipoic acid/ folic acid/ selenium dioxide/inositol/and chromium polynicotinate should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Vitamin / mineral / nutritional supplement.
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- [Mecobalamin] GI upset (iron, high-dose vitamin C).
- Hypercalcaemia (vitamin D excess).
- Neuropathy with B6 megadoses.
- Flushing (niacin). [alpha lipoic acid] GI upset (iron, high-dose vitamin C).
- Hypercalcaemia (vitamin D excess).
- Neuropathy with B6 megadoses.
- Flushing (niacin). [folic acid] Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid.
- Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy.
- Reducing the dose and administering it with meals will minimize these effects in the sensitive patient.
- Increasing fiber in the diet can relieve constipation.
- Iron may turn stools black.
- This is a harmless effect that is a result of unabsorbed iron.
- Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I. disturbances.
- Integra FTM is best absorbed when taken at bedtime.
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Mecobalamin, Folic acid.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Mecobalamin): It acts as a coenzyme for various metabolic functions such as protein synthesis and fat and carbohydrate metabolism.
Days–weeks for repletion
Depends on stores and ongoing intake
ORAL / IM / IV (selected)
depends on GI integrity, food matrix and binders (e.g. calcium/iron interactions). Fat-soluble vitamins (A,D,E,K) accumulate; water-soluble generally renally cleared.
Pregnancy, lactation & diet
[From component Folic acid] USAGE IN PREGNANCY: Before Integra FTM is prescribed for megaloblastic anemia in pregnancy, appropriate diagnostic exclusion of Addisonian pernicious anemia, (due to faulty or blocked absorption of vitamin B12, or extrinsic factor or either a genetic, immunological or surgical basis) should be carried out.
Maternal repletion often appropriate; avoid megadoses.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.